ฝัง
- เผยแพร่เมื่อ 30 ก.ย. 2024
- Dr Antonio González-Martín talks to ecancer at ESMO 2024 about mixed results from the PRIMA / ENGOT-OV26 / GOG-3012 study.
This looked at newly diagnosed advanced ovarian cancer treated with niraparib for first-line maintenance.
While the trial continues to show an increase in progression free survival vs placebo, the overall survival figures were less encouraging, with a statistically insignificant decrease from 48.8 months for placebo versus 46.6 months for nirapirib.
